Secondary Analysis of a Systematic Review: Are Antifungal Noninferiority Trials at Risk of Eroding Effectiveness Because of Biocreep?

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2021 Oct 18

PMID 34662190

Authors

Adam S Komorowski

Anthony D Bai

Anna Cvetkovic

Omar Mourad

Carson K L Lo

Xena X Li

Vaibhav Mokashi

Aidan Findlater

D Brody Duncan

Charlotte Fuller

Daniela L Leto

Deborah Yamamura

Dominik Mertz

Affiliations

Soon will be listed here.

Abstract

Noninferiority randomized controlled trial (RCT) effectiveness may erode when results favor the active control over time and when a decreasingly effective control arm is used in serial trials. We analyzed 32 antifungal noninferiority RCTs (NI-RCTs) for these scenarios in this secondary analysis of a systematic review. Our exploratory analysis suggests that the erosion risk in the effectiveness of antifungal noninferiority trials is uncommon. Findings are limited by small sample size and overall risk of bias.

References

Rex J, Bennett J, Sugar A, Pappas P, van der Horst C, Edwards J . A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med. 1994; 331(20):1325-30. DOI: 10.1056/NEJM199411173312001. View

Kohno S, Izumikawa K, Ogawa K, Kurashima A, Okimoto N, Amitani R . Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect. 2010; 61(5):410-8. DOI: 10.1016/j.jinf.2010.08.005. View

Pappas P, Rotstein C, Betts R, Nucci M, Talwar D, De Waele J . Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007; 45(7):883-93. DOI: 10.1086/520980. View

Walsh T, Finberg R, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D . Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999; 340(10):764-71. DOI: 10.1056/NEJM199903113401004. View

Molloy S, Kanyama C, Heyderman R, Loyse A, Kouanfack C, Chanda D . Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. N Engl J Med. 2018; 378(11):1004-1017. DOI: 10.1056/NEJMoa1710922. View

de Wet N, Bester A, Viljoen J, Filho F, Suleiman J, Ticona E . A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther. 2005; 21(7):899-907. DOI: 10.1111/j.1365-2036.2005.02427.x. View

Yoshida I, Saito A, Tanaka S, Choi I, Hidaka M, Miyata Y . Intravenous itraconazole compared with liposomal amphotericin B as empirical antifungal therapy in patients with neutropaenia and persistent fever. Mycoses. 2020; 63(8):794-801. PMC: 7497187. DOI: 10.1111/myc.13100. View

Maertens J, Raad I, Marr K, Patterson T, Kontoyiannis D, Cornely O . Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2015; 387(10020):760-9. DOI: 10.1016/S0140-6736(15)01159-9. View

Queiroz-Telles F, Berezin E, Leverger G, Freire A, van der Vyver A, Chotpitayasunondh T . Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J. 2008; 27(9):820-6. DOI: 10.1097/INF.0b013e31817275e6. View

10.

. White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Clin Infect Dis. 2012; 55(8):1031-46. PMC: 3657525. DOI: 10.1093/cid/cis688. View

11.

Cornely O, Maertens J, Winston D, Perfect J, Ullmann A, Walsh T . Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007; 356(4):348-59. DOI: 10.1056/NEJMoa061094. View

12.

Everson-Stewart S, Emerson S . Bio-creep in non-inferiority clinical trials. Stat Med. 2010; 29(27):2769-80. DOI: 10.1002/sim.4053. View

13.

Benjamin Jr D, Kaufman D, Hope W, Smith P, Arrieta A, Manzoni P . A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis. Pediatr Infect Dis J. 2018; 37(10):992-998. PMC: 6155365. DOI: 10.1097/INF.0000000000001996. View

14.

Huang X, Chen H, Han M, Zou P, Wu D, Lai Y . Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2012; 18(10):1509-16. DOI: 10.1016/j.bbmt.2012.03.014. View

15.

Reboli A, Rotstein C, Pappas P, Chapman S, Kett D, Kumar D . Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007; 356(24):2472-82. DOI: 10.1056/NEJMoa066906. View

16.

Walsh T, Pappas P, Winston D, Lazarus H, Petersen F, Raffalli J . Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002; 346(4):225-34. DOI: 10.1056/NEJM200201243460403. View

17.

Vazquez J, Patton L, Epstein J, Ramlachan P, Mitha I, Noveljic Z . Randomized, comparative, double-blind, double-dummy, multicenter trial of miconazole buccal tablet and clotrimazole troches for the treatment of oropharyngeal candidiasis: study of miconazole Lauriad® efficacy and safety (SMiLES). HIV Clin Trials. 2010; 11(4):186-96. DOI: 10.1310/hct1104-186. View

18.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

19.

Kuse E, Chetchotisakd P, da Cunha C, Ruhnke M, Barrios C, Raghunadharao D . Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007; 369(9572):1519-1527. DOI: 10.1016/S0140-6736(07)60605-9. View

20.

Saliba F, Pascher A, Cointault O, Laterre P, Cervera C, De Waele J . Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients. Clin Infect Dis. 2014; 60(7):997-1006. PMC: 4357288. DOI: 10.1093/cid/ciu1128. View